Impairment in functional status and survival in patients with acute myeloid leukaemia

Acute myeloid leukaemia (AML) is mainly affecting elderly patients. Elderly patients are increasingly affected by impairment of functional status (FS). FS is of prognostic relevance for survival in different tumours. Data for patients with AML are rare. Within a prospective trial we recruited patien...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2006-10, Vol.132 (10), p.665-671
Main Authors: WEDDING, Ulrich, RÖHRIG, Bernd, KLIPPSTEIN, Almuth, FRICKE, Hans-Joerg, SAYER, Herbert G, HÖFFKEN, Klaus
Format: Article
Language:English
Subjects:
Activities of Daily Living
Acute Disease
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Female
Hematologic and hematopoietic diseases
Humans
Karyotyping
Leukemia
Leukemia, Myeloid - diagnosis
Leukemia, Myeloid - mortality
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Middle Aged
Motor ability
Multivariate Analysis
Older people
Pharmacology. Drug treatments
Prognosis
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute myeloid leukaemia (AML) is mainly affecting elderly patients. Elderly patients are increasingly affected by impairment of functional status (FS). FS is of prognostic relevance for survival in different tumours. Data for patients with AML are rare. Within a prospective trial we recruited patients with newly diagnosed AML and measured FS by two different methods: Karnofsky performance status (KPS) and instrumental activities of daily living (IADL). Sixty-three patients aged 19-85 years (median 61.1) were included. Twenty-three had prior myelodisplastic syndrome (MDS), 7 favourable, 17 unfavourable karyotype. Fifty received induction chemotherapy, 13 palliative chemotherapy. Median survival was 15.2 months (95% CI, 10.8-22.3) in all patients. Age, cytogenetic risk group, and impaired KPS and IADL significantly influenced median survival in univariate analysis. Impairment of IADL was the single most predictive variable. In multivariate analysis, impairment of IADL Score (HR:4.3, 95% CI 1.7-10.5, P = 0.001) and of KPS (HR:4.8, 95% CI 1.9-12.3, P = 0.001), and unfavourable cytogenetic risk group (HR:6.0, 95% CI 2.5-14.3, P < 0.001) significantly predicted median survival. In patients with AML, FS and not age is a major predictor of survival. The influence of FS is independent from cytogenetic risk group. IADL measurement adds information to KPS. The results have to be confirmed in a large sample of patients.
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-006-0115-7